Evidium
Category: AI in Healthcare
AI-powered knowledge engineering and distribution platform for healthcare organizations Evidium was founded in 2021. The company is led by Carl Bate. Based in San Francisco, United States. Team size: 31-50. Total funding raised: $22M. Latest round: Series A. Key investors include Health2047 (American Medical Association venture studio), WGG Partners, Interwoven Ventures, Mindset Ventures, x.AI, Perplexity, Innovaccer.
- Founded
- 2021
- Headquarters
- San Francisco, United States
- Team size
- 31-50
- Total funding
- $22M
Value proposition
Delivers referenced AI systems that ensure accuracy and traceability in computational medical knowledge, addressing critical needs in clinical decision-making and research
Products and solutions
Neurosymbolic AI platform, Clinical decision support systems, Medical research analytics tools, Predictive clinical disease state modeling, Regulatory compliance solutions, Computational medical reasoning platform
Unique value
Referenced-traced AI architecture ensuring verifiable medical knowledge outputs through neurosymbolic approach combining neural networks with symbolic reasoning
Target customer
Healthcare providers, pharmaceutical companies, self-insured stakeholders, insurers, and medical research institutions
Industries served
Hospital systems, Self-insured organizations, Insurance providers, Pharmaceutical development, Medical device companies, Healthtech startups, Academic medical research
Technology advantage
Proprietary computational medical knowledge graph with 20+ years of curated clinical evidence, neurosymbolic architecture with multiple patents pending
How they differentiate
Evidium differentiates itself through 'referenced AI' and computational medical knowledge, emphasizing transparency, reliability, and traceability in AI-driven healthcare solutions using neurosymbolic architecture
Main competitors
Argon AI, Bloomfire, Ngram, GenexAI, Basil Systems, Neuroute, PulseLife, Medinfo
Key partnerships
Health2047 (American Medical Association venture studio), Oracle Cloud Infrastructure, WGG Partners, Interwoven Ventures, Mindset Ventures, x.AI, Perplexity, Innovaccer
Notable customers
Partnerships with major healthcare organizations (specific names not disclosed publicly)
Major milestones
Raised $22M Series A funding (November 2025), Established referenced AI platform for computational medical knowledge, Built enterprise partnerships with healthcare systems, Selected Oracle Cloud Infrastructure for AI model development, Filed patent for patient state determination technology
Growth metrics
Not publicly disclosed (private company)
Market positioning
Positioned as a leader in enterprise-grade healthcare AI, focusing on clinical decision support and knowledge management for large healthcare organizations with emphasis on referenced AI
Geographic focus
Primarily North American market with partnerships with major U.S.-based healthcare systems and consulting firms
Patents and IP
1 patent application filed January 8, 2024 for 'Determination of patient state' (application pending)
About Carl Bate
Over 20 years of experience in technology leadership roles at Arthur D. Little (Partner & Co-Lead for AI), Capgemini (CTO), and enterprise AI strategy. Recognized for developing referenced AI systems in healthcare.
Official website: https://www.evidium.com